These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33753834)

  • 1. TMAO: a potential mediator of clopidogrel resistance.
    Ma R; Fu W; Zhang J; Hu X; Yang J; Jiang H
    Sci Rep; 2021 Mar; 11(1):6580. PubMed ID: 33753834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention.
    Ahn SG; Lee SH; Sung JK; Kim JY; Yoon J
    Platelets; 2011; 22(4):305-7. PubMed ID: 21480769
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
    Labarthe B; Babin J; Bryckaert M; Théroux P; Bonnefoy A
    Br J Pharmacol; 2012 May; 166(1):221-31. PubMed ID: 21950486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
    Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
    Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.
    Chirumamilla AP; Maehara A; Mintz GS; Mehran R; Kanwal S; Weisz G; Hassanin A; Hakim D; Guo N; Baber U; Pyo R; Moses JW; Fahy M; Kovacic JC; Dangas GD
    JACC Cardiovasc Imaging; 2012 May; 5(5):540-9. PubMed ID: 22595163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
    Gratsianskiĭ NA
    Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
    Perneby C; Wallén NH; Hofman-Bang C; Tornvall P; Ivert T; Li N; Hjemdahl P
    Thromb Haemost; 2007 Dec; 98(6):1316-22. PubMed ID: 18064330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis.
    Liu Z; Xiang Q; Mu G; Xie Q; Zhou S; Wang Z; Chen S; Hu K; Gong Y; Jiang J; Cui Y
    Platelets; 2020; 31(1):3-14. PubMed ID: 30744477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
    Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
    Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
    Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
    Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response.
    Pasalic L; Wing-Lun E; Lau JK; Campbell H; Pennings GJ; Lau E; Connor D; Liang HP; Muller D; Kritharides L; Hogg PJ; Chen VM
    J Thromb Haemost; 2018 Jun; 16(6):1198-1210. PubMed ID: 29569428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet Metabolism in Clopidogrel Resistant and Sensitive Patients With Ischemic Heart Disease].
    Grinshtein IY; Savchenko AA; Grinshtein YI; Filonenko IV; Kosinova AA
    Kardiologiia; 2016 Oct; 56(10):5-12. PubMed ID: 28290889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The STIB score: a simple clinical test to predict clopidogrel resistance.
    Legrand D; Barbato E; Chenu P; Magne J; Vrolix M; Wijns W; Legrand V;
    Acta Cardiol; 2015 Oct; 70(5):516-21. PubMed ID: 26567810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.